Antithrombin-lowering in hemophilia: a closer look at fitusiran
Por um escritor misterioso
Descrição
New hemophilia guidelines introduced at WFH Virtual Summit 2020 – Canadian Hemophilia Society
Frontiers The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A
Fitusiran Reduces Bleeding in Hemophilia A, B, Regardless of Inhibitors
Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation
Frontiers Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications
A Molecular Revolution in the Treatment of Hemophilia. - Abstract - Europe PMC
Positive Phase III results for fitusiran in hemophilia
siRNA against anti-thrombin reduces bleeding in hemophilia
PDF) An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
Antithrombin-lowering in hemophilia: a closer look at fitusiran - Research and Practice in Thrombosis and Haemostasis
PDF) Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
Hemostatic disorders and hereditary angioedema
Fitusiran: A Game-Changing Drug for Hemophilia Patients
Innovations in Managing Hemophilia
de
por adulto (o preço varia de acordo com o tamanho do grupo)
